AbbVie Inc. (NEO: ABBV)

Market Cap	445.94B
Revenue (ttm)	75.02B
Net Income (ttm)	6.86B
Shares Out	n/a
EPS (ttm)	3.88
PE Ratio	64.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	24.74
Previous Close	24.78
Day's Range	24.74 - 25.50
52-Week Range	22.21 - 30.02
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 50,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.

Financial numbers in USD